샘플 요청 목록

 카트 문의
시장보고서
상품코드
1543990

세계의 항정신병약 시장

Antipsychotic Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항정신병약 시장은 2030년까지 273억 달러에 달할 전망

2023년에 173억 달러로 추정되는 세계의 항정신병약 시장은 2023-2030년 CAGR 6.7%로 성장하며, 2030년에는 273억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석하고 있는 부문의 하나인 제2세대 항정신병약은 CAGR 7.3%를 기록하며, 분석 기간 종료시에는 157억 달러에 달할 것으로 예측됩니다. 제1세대 항정신병약 부문의 성장률은 분석 기간 중 CAGR 6.0%로 추정됩니다.

미국 시장은 45억 달러, 중국은 CAGR 10.1%로 성장 예측

미국의 항정신병약 시장은 2023년에 45억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2023-2030년 CAGR을 10.1%로, 2030년까지 시장 규모가 66억 달러에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 6.1%로 예측됩니다. 유럽에서는 독일이 CAGR 4.2%로 성장할 것으로 예측됩니다.

세계의 항정신병약 시장 - 주요 동향과 촉진요인 정리

항정신병약이란 무엇인가?

항정신병약은 주로 망상, 환각, 정신분열증 및 양극성 장애와 같은 정신질환을 관리하기 위해 사용되는 약물입니다. 이 약물은 뇌의 신경 전달 물질, 특히 정신병 증상의 병태 생리학에 관여하는 도파민과 세로토닌의 작용을 변화시킴으로써 작용합니다. 항정신병약에는 크게 두 가지 주요 범주가 있는데, 정형 항정신병약(1세대)과 비정형 항정신병약(2세대)이 있습니다. 할로페리돌, 클로르프로마딘과 같은 정형 항정신병약은 1950년대에 개발되었으며 주로 도파민 수용체를 표적으로 삼습니다. 리스페리돈, 올란자핀, 아리피프라졸과 같은 비정형 항정신병약은 나중에 등장했으며 도파민 수용체와 세로토닌 수용체 모두에 작용하며 운동 장애와 관련된 부작용이 적은 경우가 많습니다. 이러한 약물은 정신병 에피소드의 심각성을 줄이고 심각한 정신 질환을 가진 사람들의 삶의 질을 향상시키는 데 매우 중요합니다.

항정신병약은 어떻게 처방되고 투여되는가?

항정신병약의 처방과 투약은 특정 진단, 증상의 심각성, 치료에 대한 환자의 반응과 같은 요소를 고려하여 환자 개개인의 필요에 따라 결정됩니다. 이러한 약물은 정제, 캡슐, 액상 형태로 경구 투여하거나 장기지속형 주사제를 통해 투여할 수 있습니다. 장기지속형 주사제(LAI)는 치료 약물 수준을 장기간 유지할 수 있으며, 복약 순응도를 높이고 입원 빈도를 줄일 수 있으며, 인기를 끌고 있습니다. 치료 요법은 종종 저용량으로 시작하여 부작용을 최소화하기 위해 점진적으로 용량을 늘리는 방식으로 시작됩니다. 잠재적인 부작용을 관리하고 필요에 따라 용량을 조정하기 위해서는 의료 전문가의 정기적인 모니터링이 필수적입니다. 또한 항정신병약 치료는 종종 정신치료 및 기타 지지 요법과 병용하여 정신질환을 관리하기 위한 총체적인 접근법을 제공합니다.

항정신병약 개발의 최신 동향은?

항정신병약 개발은 빠르게 발전하고 있는 분야로, 약효를 개선하고 부작용을 줄이기 위한 지속적인 연구와 기술 혁신이 그 원동력이 되고 있습니다. 중요한 동향 중 하나는 치료 효과를 높이기 위해 서로 다른 신경 전달 체계와 특정 수용체 아형을 표적으로 하는 새로운 작용기전을 가진 약물의 개발에 초점을 맞추고 있다는 점입니다. 유전자 및 바이오마커 연구를 통해 환자 개개인프로파일에 따라 맞춤형 치료를 할 수 있는 개인맞춤형 의료 접근법도 각광을 받고 있습니다. 또 다른 동향는 증상과 복약 순응도를 실시간으로 모니터링하기 위해 모바일 앱과 웨어러블 기기 등 디지털 헬스 기술을 통합하는 것입니다. 항정신병약과 다른 약리학적 약물 및 인지행동치료(CBT)와 같은 비약리학적 개입을 결합한 보조 요법의 탐구도 눈에 띕니다. 이러한 추세는 혁신적이고 환자 중심적인 접근 방식을 통해 정신건강 치료를 발전시키려는 보다 광범위한 노력을 반영하고 있습니다.

항정신병약 시장의 성장을 이끄는 요인은 무엇인가?

항정신병 치료제 시장의 성장은 여러 가지 요인에 의해 주도되고 있으며, 각 요인은 항정신병 치료제 수요 증가와 채택에 기여하고 있습니다. 주요 요인 중 하나는 전 세계에서 정신질환의 유병률이 증가하면서 효과적인 항정신병 치료제의 필요성이 증가하고 있다는 점입니다. 장시간 작용하는 주사제, 디지털 건강 툴 등 약물 제형 및 전달 기술의 발전은 환자의 순응도와 치료 결과를 향상시킵니다. 정신질환의 유전적, 분자적 기반에 대한 이해는 보다 표적화되고 효과적인 약물의 개발을 촉진하고 있습니다. 또한 정신건강 문제의 비공식화와 인식 개선 캠페인 증가는 조기 진단과 조기 치료로 이어져 환자 기반을 확대할 수 있습니다. 또한 1차 진료 및 광범위한 의료 인프라에 정신건강 서비스가 통합되면서 항정신병 약품에 대한 접근성이 향상되고 있습니다. 또한 제약회사들의 연구개발에 대한 막대한 투자와 공중보건에 대한 노력은 항정신병약 시장의 지속적인 발전을 지원하고 있습니다. 이러한 요인들이 복합적으로 작용하여 항정신병약은 강력한 성장 궤도를 그리며 중증 정신질환을 앓고 있는 사람들의 복잡하고 다양한 니즈를 충족시키고 있습니다.

조사 대상 기업의 예(주목 44사)

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.09.03

Global Antipsychotic Drugs Market to Reach US$27.3 Billion by 2030

The global market for Antipsychotic Drugs estimated at US$17.3 Billion in the year 2023, is expected to reach US$27.3 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in the First Generation Antipsychotic Drugs segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 10.1% CAGR

The Antipsychotic Drugs market in the U.S. is estimated at US$4.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Antipsychotic Drugs Market - Key Trends and Drivers Summarized

What Are Antipsychotic Drugs and How Do They Work?

Antipsychotic drugs are medications used primarily to manage psychosis, including delusions, hallucinations, and disorders such as schizophrenia and bipolar disorder. These drugs function by altering the effects of neurotransmitters in the brain, particularly dopamine and serotonin, which are implicated in the pathophysiology of psychotic symptoms. There are two main categories of antipsychotic drugs: typical (first-generation) and atypical (second-generation). Typical antipsychotics, such as haloperidol and chlorpromazine, were developed in the 1950s and primarily target dopamine receptors. Atypical antipsychotics, such as risperidone, olanzapine, and aripiprazole, emerged later and act on both dopamine and serotonin receptors, often with fewer side effects related to movement disorders. These medications are crucial in reducing the severity of psychotic episodes, improving the quality of life for individuals with severe mental health conditions.

How Are Antipsychotic Drugs Prescribed and Administered?

The prescription and administration of antipsychotic drugs are tailored to the individual needs of patients, considering factors such as the specific diagnosis, symptom severity, and patient response to treatment. These medications can be administered orally in the form of tablets, capsules, or liquid solutions, or through long-acting injectable formulations. Long-acting injectables (LAIs) have gained popularity due to their ability to maintain therapeutic drug levels over extended periods, enhancing adherence and reducing the frequency of hospitalizations. The treatment regimen often begins with a low dose that is gradually increased to minimize side effects. Regular monitoring by healthcare professionals is essential to manage potential adverse effects and adjust dosages as necessary. Additionally, antipsychotic treatment is frequently combined with psychotherapy and other supportive measures to provide a holistic approach to managing mental health disorders.

What Are the Latest Trends in Antipsychotic Drug Development?

The development of antipsychotic drugs is a rapidly evolving field, driven by ongoing research and innovation aimed at improving efficacy and reducing side effects. One significant trend is the focus on developing drugs with novel mechanisms of action, targeting different neurotransmitter systems or specific receptor subtypes to enhance therapeutic outcomes. Personalized medicine approaches are also gaining traction, with genetic and biomarker studies informing more tailored treatments based on individual patient profiles. Another trend is the integration of digital health technologies, such as mobile apps and wearable devices, to monitor symptoms and medication adherence in real time. The exploration of adjunctive therapies, combining antipsychotic drugs with other pharmacological agents or non-pharmacological interventions like cognitive-behavioral therapy (CBT), is also prominent. These trends reflect a broader commitment to advancing mental health treatment through innovative and patient-centered approaches.

What Is Driving the Growth in the Antipsychotic Drug Market?

The growth in the antipsychotic drug market is driven by several factors, each contributing to the increasing demand and adoption of these medications. One of the primary drivers is the rising prevalence of mental health disorders globally, which underscores the need for effective antipsychotic treatments. Technological advancements in drug formulation and delivery, such as long-acting injectables and digital health tools, enhance patient adherence and therapeutic outcomes. The expanding understanding of the genetic and molecular underpinnings of psychiatric disorders propels the development of more targeted and effective drugs. Furthermore, the destigmatization of mental health issues and increasing awareness campaigns lead to earlier diagnosis and treatment, thereby expanding the patient base. The integration of mental health services into primary care settings and the broader healthcare infrastructure also facilitates access to antipsychotic medications. Additionally, significant investments in research and development by pharmaceutical companies and public health initiatives support the continuous evolution of the antipsychotic drug market. Collectively, these factors create a robust growth trajectory for antipsychotic medications, addressing the complex and diverse needs of individuals with severe mental health conditions.

Select Competitors (Total 44 Featured) -

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Antipsychotic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Mental Health Disorders Spurs Market Growth
    • Technological Advancements Propel Growth in Antipsychotic Drug Development
    • Novel Mechanisms of Action Expand Addressable Market Opportunity
    • Personalized Medicine Approaches Strengthen Business Case for Tailored Treatments
    • Adjunctive Therapies Accelerate Demand for Combined Treatment Regimens
    • Long-Acting Injectables Sustain Growth by Enhancing Patient Compliance
    • Increasing Awareness and Destigmatization Throw Spotlight on Antipsychotic Treatments
    • Expansion of Mental Health Services into Primary Care Drives Market Expansion
    • Improved Understanding of Psychiatric Disorders Propels Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Schizophrenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Bipolar Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Antipsychotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antipsychotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antipsychotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제